Banarian Nordic Res (BVNKF) 34.5000 $BVNKF
Bavarian Nordic to Present at Jefferies 2016 Healthcare Conference in New York
Globe Newswire - Thu Jun 02, 10:30AM CDT
COPENHAGEN, Denmark - June 2, 2016 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that Paul Chaplin, President & Chief Executive Officer will provide a corporate presentation at the Jefferies 2016 Healthcare Conference in New York on Wednesday, June 8, 2016 at 10:30 a.m. ET.
Bavarian Nordic Launches Share Buy-Back Program to Hedge Incentive Scheme Obligations
Globe Newswire - Thu May 26, 1:00AM CDT
COPENHAGEN, Denmark, May 26, 2016 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that its Board of Directors has decided to launch a share buy-back program, under which the Company intends to buy back 11,144 of its own shares. The purpose of the share buy-back program is to meet the Company's obligations arising from the share-based incentive program for the Executive Management. In March 2016, the Board of Directors decided to postpone the payment of half of the achieved cash bonus for members of the Executive Management for 3 years, converting the postponed bonus into restricted stock units to further increase the long-term shared interests between the Executive Management and the Company's shareholders. See company announcement no. 5 / 2016 for further details.
Bavarian Nordic Announces Positive Top Line Results from a Phase 1 Trial of a Novel, Broad Spectrum RSV Vaccine in Healthy Adult and Elderly Populations
Globe Newswire - Mon May 23, 6:01AM CDT
- Vaccine significantly boosted antibodies and T cells against RSV in the majority of elderly subjects
Bavarian Nordic Announces USD 100 Million Supply Contract for IMVAMUNE Smallpox Vaccine with the U.S. Government
Globe Newswire - Thu May 19, 12:31AM CDT
- New order affirms the U.S. Government commitment to freeze-dried IMVAMUNE
Bavarian Nordic Announces Interim Results for the First Three Months of 2016
Globe Newswire - Fri May 13, 12:47AM CDT
COPENHAGEN, Denmark, May 13, 2016 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today its interim financial results for the first three months of 2016. Below is a summary of business progress and financial performance for the period. The full interim report is attached as a PDF file and can be found on the company's website, www.bavarian-nordic.com.
Bavarian Nordic to Host First Quarter 2016 Results Conference Call
Globe Newswire - Mon May 09, 10:30AM CDT
COPENHAGEN, Denmark - May 9, 2016 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) will announce its 2016 first quarter results on Friday, May 13, 2016, prior to market open.
Bavarian Nordic Applauds Announcement of Positive Data for Ebola Vaccine Regimen Published in JAMA
Globe Newswire - Tue Apr 19, 10:33AM CDT
- Ebola vaccine regimen produced an antibody response in 100 percent of healthy volunteers that was sustained 8 months following immunization, indicating potential for a durable response
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise
Globe Newswire - Mon Mar 21, 4:38AM CDT
COPENHAGEN, Denmark, March 21, 2016 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the Company's share capital has been increased by nominally DKK 460,410 as a consequence of employees' exercise of warrants.
Anthrax Market Pipeline Global Review Research Report for H2 2015
PR Newswire - Thu Mar 17, 9:00PM CDT
The "Anthrax - Pipeline Review, H2 2015" market research report provides an overview of the Anthrax's therapeutic pipeline and helps enhance decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
DVAX: 14.84 (-0.28), TTPH: 4.32 (-0.05), ADRO: 11.91 (-0.33), EBS: 28.78 (+0.07), UTHR: 107.73 (-1.16), BMY: 73.78 (unch), PFNX: 8.42 (-0.17), PIP: 2.48 (+0.05), IBIO: 0.67 (-0.07), OGEN: 0.59 (+0.04)
Bavarian Nordic Awards Restricted Stock Units to Executive Management
Globe Newswire - Mon Mar 07, 8:51AM CST
COPENHAGEN, Denmark, March 7, 2016 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the Company has awarded restricted stock units to members of the Executive Management.
Bavarian Nordic Announces Annual Report 2015
Globe Newswire - Mon Mar 07, 5:50AM CST
COPENHAGEN, Denmark, March 7, 2016 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today its Annual Report for 2015. Below is a summary of business progress and financial performance for the year, and financial outlook for 2016 from the report. The full report is attached as a PDF file and can be found on the company's website, www.bavarian-nordic.com.
Colorectal Cancer Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/44bmjz/colorectal_cancer) has announced the addition of the "Colorectal Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colorectal Cancerand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Colorectal CancerOverview - Therapeutics Development - Pipeline Products for Colorectal Cancer- Overview - Pipeline Products for Colorectal Cancer- Comparative Analysis - Colorectal Cancer- Therapeutics under Development by Companies - Colorectal Cancer- Therapeutics under Investigation by Universities/Institutes - Colorectal Cancer- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Colorectal Cancer- Products under Development by Companies - Colorectal Cancer- Products under Investigation by Universities/Institutes - Colorectal Cancer- Companies Involved in Therapeutics Development Companies Mentioned - Sample List of the 200 Companies Featured - 2cureX ApS - 3-V Biosciences, Inc. - 4SC AG - AB Science SA - AbbVie Inc. - AbGenomics International, Inc. - Actinium Pharmaceuticals, Inc. - Adamed Sp. z o.o. - Advaxis, Inc. - Advenchen Laboratories, LLC - Alchemia Limited - Allinky Biopharma - Amgen Inc. - Antibe Therapeutics, Inc. - Apexigen, Inc. - Aphios Corporation - Aposense Ltd. - Arisaph Pharmaceuticals, Inc. - ArQule, Inc. - Array BioPharma Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - AVEO Pharmaceuticals, Inc. - Basilea Pharmaceutica AG - Bavarian Nordic A/S - Baxalta Incorporated - Bayer AG - BeiGene(Beijing) Co.,Ltd - BioAtla, LLC - Biocon Limited - Bionomics Limited - Bionovis SA - Biotecnol, Inc. For more information visit http://www.researchandmarkets.com/research/44...tal_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ADXS: 8.08 (-0.09), ARQL: 1.75 (-0.10), AMGN: 154.27 (-0.01), ATNM: 1.79 (-0.05), AZN: 30.15 (-0.27), AVEO: 0.93 (-0.01), ABBV: 61.92 (-0.79), BXLT: 46.02 (-0.18), ARRY: 3.62 (-0.01)
Metastatic Colorectal Cancer Pipeline Review, H2 2015
M2 - Mon Feb 08, 11:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/pdf2gt/metastatic) has announced the addition of the "Metastatic Colorectal Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Colorectal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Colorectal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Metastatic Colorectal Cancer Overview - Therapeutics Development - Pipeline Products for Metastatic Colorectal Cancer - Overview - Pipeline Products for Metastatic Colorectal Cancer - Comparative Analysis - Metastatic Colorectal Cancer - Therapeutics under Development by Companies - Metastatic Colorectal Cancer - Therapeutics under Investigation by Universities/Institutes - Metastatic Colorectal Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Metastatic Colorectal Cancer - Products under Development by Companies - Metastatic Colorectal Cancer - Products under Investigation by Universities/Institutes - Metastatic Colorectal Cancer - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - AB Science SA - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Advenchen Laboratories, LLC - Alchemia Limited - Amgen Inc. - Apexigen, Inc. - ArQule, Inc. - Array BioPharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Bavarian Nordic A/S - Baxalta Incorporated - Bayer AG - Biocon Limited - Bionovis SA - Biothera, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Celltrion, Inc. - Celon Pharma Sp. z o.o. - Cornerstone Pharmaceuticals, Inc. - DanDrit Biotech A/S - Dr. Reddy's Laboratories Limited - EirGenix Inc. - Eisai Co., Ltd. - Eli Lilly and Company - EnGeneIC Ltd - Epirus Biopharmaceuticals, Inc. - Etubics Corporation - Exelixis, Inc. For more information visit http://www.researchandmarkets.com/research/pdf2gt/metastatic
ARQL: 1.75 (-0.10), AMGN: 154.27 (-0.01), LLY: 79.64 (+0.69), BMY: 73.78 (unch), ATNM: 1.79 (-0.05), AZN: 30.15 (-0.27), AVEO: 0.93 (-0.01), ABBV: 61.92 (-0.79), BXLT: 46.02 (-0.18), EXEL: 8.05 (-0.12), CELGZ: 1.35 (-0.05), ARRY: 3.62 (-0.01)
Global Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Pipeline Review, H2 2015
M2 - Fri Feb 05, 10:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/rv4d7j/hormone) has announced the addition of the "Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Overview - Therapeutics Development - Pipeline Products for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Overview - Pipeline Products for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Development by Companies - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Investigation by Universities/Institutes - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Development by Companies - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Investigation by Universities/Institutes - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Companies Involved in Therapeutics Development Companies Featured - Partial List - A. Menarini Industrie Farmaceutiche Riunite Srl - AB Science SA - AbbVie Inc. - Adamis Pharmaceuticals Corporation - Advaxis, Inc. - Aeterna Zentaris Inc. - Alethia Biotherapeutics Inc. - Ambrx, Inc. - Amgen Inc. - AnGes MG, Inc. - Angion Biomedica Corp. - Aphios Corporation - Armour Therapeutics Inc. - Arno Therapeutics, Inc. - Arrowhead Research Corporation - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - Bavarian Nordic A/S - Bayer AG - Beta Pharma, Inc. - BIND Therapeutics, Inc. - Bio-Cancer Treatment International Limited - Biscayne Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CellCentric Ltd - Celldex Therapeutics, Inc. - Corcept Therapeutics Incorporated - CureVac GmbH - CytoVac A/S - DexTech Medical AB - Eisai Co., Ltd. - Eli Lilly and Company For more information visit http://www.researchandmarkets.com/research/rv4d7j/hormone
ADXS: 8.08 (-0.09), ARWR: 5.37 (-0.13), AMBX: (), CLDX: 4.52 (-0.07), ADMP: 3.19 (+0.24), AMGN: 154.27 (-0.01), LLY: 79.64 (+0.69), BIND: 0.73 (+0.33), BMY: 73.78 (unch), AZN: 30.15 (-0.27), ABBV: 61.92 (-0.79), CORT: 5.58 (+0.03)
Respiratory Syncytial Virus (RSV) Infections Pipeline Review, H2 2015
M2 - Tue Feb 02, 6:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/5krjz7/respiratory) has announced the addition of the "Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Respiratory Syncytial Virus (RSV) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Respiratory Syncytial Virus (RSV) Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Respiratory Syncytial Virus (RSV) Infections Overview - Therapeutics Development - Pipeline Products for Respiratory Syncytial Virus (RSV) Infections - Overview - Pipeline Products for Respiratory Syncytial Virus (RSV) Infections - Comparative Analysis - Respiratory Syncytial Virus (RSV) Infections - Therapeutics under Development by Companies - Respiratory Syncytial Virus (RSV) Infections - Therapeutics under Investigation by Universities/Institutes - Respiratory Syncytial Virus (RSV) Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Respiratory Syncytial Virus (RSV) Infections - Products under Development by Companies - Respiratory Syncytial Virus (RSV) Infections - Products under Investigation by Universities/Institutes - Respiratory Syncytial Virus (RSV) Infections - Companies Involved in Therapeutics Development - 3-V Biosciences, Inc. - Ablynx NV - ADMA Biologics, Inc. - Agilvax, Inc. - AmVac AG - Aridis Pharmaceuticals LLC - Bavarian Nordic A/S - Biota Pharmaceuticals, Inc. - Emergent BioSolutions Inc. - Evec, Inc. - F. Hoffmann-La Roche Ltd. - Folia Biotech Inc. - GenVec, Inc. - Gilead Sciences, Inc. - GlaxoSmithKline Plc - Globavir Biosciences, Inc. - Humabs BioMed SA - iBio, Inc. - ILiAD Biotechnologies, LLC - MedImmune, LLC - Medivir AB - Merck & Co., Inc. - MSM Protein Technologies, Inc. - Mucosis B.V. - NanoBio Corporation - Navigen Pharmaceuticals, Inc. - Romark Laboratories, L.C. - Sirnaomics, Inc. - Spider Biotech - Spring Bank Pharmaceuticals, Inc. - Takeda Pharmaceutical Company Limited - TechnoVax, Inc. - The International Biotechnology Center (IBC) Generium - Vaxart, Inc. - VBI Vaccines Inc. For more information visit http://www.researchandmarkets.com/research/5k...espiratory
ADMA: 6.26 (-0.09), EBS: 28.78 (+0.07), BOTA: 1.55 (-0.04), VBIV: 3.73 (-0.09), GSK: 43.50 (+0.33), GILD: 83.89 (-0.97), MRK: 58.00 (+0.06), IBIO: 0.67 (-0.07)
Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H2 2015 Featuring Bavarian Nordic, Emergent BioSolutions, Soligenix & Syntiron
M2 - Thu Jan 28, 4:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/fkk4sx/burkholderia) has announced the addition of the "Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Burkholderia pseudomallei Infections (Melioidosis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Burkholderia pseudomallei Infections (Melioidosis) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Burkholderia pseudomallei Infections (Melioidosis) Overview - Therapeutics Development - Pipeline Products for Burkholderia pseudomallei Infections (Melioidosis) - Overview - Pipeline Products for Burkholderia pseudomallei Infections (Melioidosis) - Comparative Analysis - Burkholderia pseudomallei Infections (Melioidosis) - Therapeutics under Development by Companies - Burkholderia pseudomallei Infections (Melioidosis) - Therapeutics under Investigation by Universities/Institutes - Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Burkholderia pseudomallei Infections (Melioidosis) - Products under Development by Companies - Burkholderia pseudomallei Infections (Melioidosis) - Products under Investigation by Universities/Institutes - Burkholderia pseudomallei Infections (Melioidosis) - Companies Involved in Therapeutics Development - Bavarian Nordic A/S - Emergent BioSolutions Inc. - Soligenix, Inc. - Syntiron LLC For more information visit http://www.researchandmarkets.com/research/fk...rkholderia
EBS: 28.78 (+0.07)
Bavarian Nordic Announces 3:1 Effective Split of American Depositary Shares
Thomson Reuters ONE - Tue Jan 05, 8:34AM CST
COPENHAGEN, Denmark, January 5, 2016 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that it will change the ratio of its American Depositary Shares ("ADSs"
, which are currently traded over-the-counter in the United States, from one (1) ADS per one (1) share of Bavarian Nordic, nominal value DKK 10 per share (each, a "Share" , to three (3) ADSs per one (1) Share. This ratio change is equivalent in effect to a 3:1 split of the ADSs. Each ADS currently represents an underlying interest in one (1) Share; following the ADS ratio change, each ADS will represent an underlying interest in one-third (1/3) of a Share, and three (3) ADSs will together represent an interest in one (1) Share. The record date for the ADS ratio change is January 15, 2016 (at close of business in New York) and the effective date for the ADS ratio change is January 19, 2016 (at open of business in New York).
Bavarian Nordic Files Registration Statement for Proposed Initial Public Offering of ADSs in the United States
Thomson Reuters ONE - Mon Jan 04, 8:02AM CST
COPENHAGEN, Denmark, January 4, 2016 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today the filing of a Form F-1 Registration Statement with the U.S. Securities and Exchange Commission (the "SEC" for a proposed initial public offering of American Depositary Shares ("ADSs" . The application is being made to list the ADSs on The NASDAQ Global Select Market in the United States under the symbol "BAVN." ADSs are U.S. dollar-denominated negotiable instruments issued by a depositary bank that facilitate U.S. trading and investment in shares of non-U.S. companies. The Form F-1 Registration Statement filed with the SEC will not contain any material information, not already published by Bavarian Nordic.
Global Bavarian Nordic A/S Product Pipeline Review 2015
M2 - Thu Dec 24, 3:09AM CST
AcuteMarketReports.com has announced the addition of "Global Bavarian Nordic A/S Product Pipeline Review 2015 "Market Research Report to their Database.
Bavarian Nordic Enters Licensing and Collaboration Agreement with Janssen for MVA-BN(R) in the Development of a Therapeutic HPV Vaccine
Thomson Reuters ONE - Fri Dec 18, 12:31AM CST
- Total potential agreement value USD 171 million including upfront and milestone payments
Bavarian Nordic to Present at Jefferies 2016 Healthcare Conference in New York
Globe Newswire - Thu Jun 02, 10:30AM CDT
COPENHAGEN, Denmark - June 2, 2016 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that Paul Chaplin, President & Chief Executive Officer will provide a corporate presentation at the Jefferies 2016 Healthcare Conference in New York on Wednesday, June 8, 2016 at 10:30 a.m. ET.
Bavarian Nordic Launches Share Buy-Back Program to Hedge Incentive Scheme Obligations
Globe Newswire - Thu May 26, 1:00AM CDT
COPENHAGEN, Denmark, May 26, 2016 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that its Board of Directors has decided to launch a share buy-back program, under which the Company intends to buy back 11,144 of its own shares. The purpose of the share buy-back program is to meet the Company's obligations arising from the share-based incentive program for the Executive Management. In March 2016, the Board of Directors decided to postpone the payment of half of the achieved cash bonus for members of the Executive Management for 3 years, converting the postponed bonus into restricted stock units to further increase the long-term shared interests between the Executive Management and the Company's shareholders. See company announcement no. 5 / 2016 for further details.
Bavarian Nordic Announces Positive Top Line Results from a Phase 1 Trial of a Novel, Broad Spectrum RSV Vaccine in Healthy Adult and Elderly Populations
Globe Newswire - Mon May 23, 6:01AM CDT
- Vaccine significantly boosted antibodies and T cells against RSV in the majority of elderly subjects
Bavarian Nordic Announces USD 100 Million Supply Contract for IMVAMUNE Smallpox Vaccine with the U.S. Government
Globe Newswire - Thu May 19, 12:31AM CDT
- New order affirms the U.S. Government commitment to freeze-dried IMVAMUNE
Bavarian Nordic Announces Interim Results for the First Three Months of 2016
Globe Newswire - Fri May 13, 12:47AM CDT
COPENHAGEN, Denmark, May 13, 2016 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today its interim financial results for the first three months of 2016. Below is a summary of business progress and financial performance for the period. The full interim report is attached as a PDF file and can be found on the company's website, www.bavarian-nordic.com.
Bavarian Nordic to Host First Quarter 2016 Results Conference Call
Globe Newswire - Mon May 09, 10:30AM CDT
COPENHAGEN, Denmark - May 9, 2016 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) will announce its 2016 first quarter results on Friday, May 13, 2016, prior to market open.
Bavarian Nordic Applauds Announcement of Positive Data for Ebola Vaccine Regimen Published in JAMA
Globe Newswire - Tue Apr 19, 10:33AM CDT
- Ebola vaccine regimen produced an antibody response in 100 percent of healthy volunteers that was sustained 8 months following immunization, indicating potential for a durable response
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise
Globe Newswire - Mon Mar 21, 4:38AM CDT
COPENHAGEN, Denmark, March 21, 2016 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the Company's share capital has been increased by nominally DKK 460,410 as a consequence of employees' exercise of warrants.
Anthrax Market Pipeline Global Review Research Report for H2 2015
PR Newswire - Thu Mar 17, 9:00PM CDT
The "Anthrax - Pipeline Review, H2 2015" market research report provides an overview of the Anthrax's therapeutic pipeline and helps enhance decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
DVAX: 14.84 (-0.28), TTPH: 4.32 (-0.05), ADRO: 11.91 (-0.33), EBS: 28.78 (+0.07), UTHR: 107.73 (-1.16), BMY: 73.78 (unch), PFNX: 8.42 (-0.17), PIP: 2.48 (+0.05), IBIO: 0.67 (-0.07), OGEN: 0.59 (+0.04)
Bavarian Nordic Awards Restricted Stock Units to Executive Management
Globe Newswire - Mon Mar 07, 8:51AM CST
COPENHAGEN, Denmark, March 7, 2016 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the Company has awarded restricted stock units to members of the Executive Management.
Bavarian Nordic Announces Annual Report 2015
Globe Newswire - Mon Mar 07, 5:50AM CST
COPENHAGEN, Denmark, March 7, 2016 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today its Annual Report for 2015. Below is a summary of business progress and financial performance for the year, and financial outlook for 2016 from the report. The full report is attached as a PDF file and can be found on the company's website, www.bavarian-nordic.com.
Colorectal Cancer Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/44bmjz/colorectal_cancer) has announced the addition of the "Colorectal Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colorectal Cancerand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Colorectal CancerOverview - Therapeutics Development - Pipeline Products for Colorectal Cancer- Overview - Pipeline Products for Colorectal Cancer- Comparative Analysis - Colorectal Cancer- Therapeutics under Development by Companies - Colorectal Cancer- Therapeutics under Investigation by Universities/Institutes - Colorectal Cancer- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Colorectal Cancer- Products under Development by Companies - Colorectal Cancer- Products under Investigation by Universities/Institutes - Colorectal Cancer- Companies Involved in Therapeutics Development Companies Mentioned - Sample List of the 200 Companies Featured - 2cureX ApS - 3-V Biosciences, Inc. - 4SC AG - AB Science SA - AbbVie Inc. - AbGenomics International, Inc. - Actinium Pharmaceuticals, Inc. - Adamed Sp. z o.o. - Advaxis, Inc. - Advenchen Laboratories, LLC - Alchemia Limited - Allinky Biopharma - Amgen Inc. - Antibe Therapeutics, Inc. - Apexigen, Inc. - Aphios Corporation - Aposense Ltd. - Arisaph Pharmaceuticals, Inc. - ArQule, Inc. - Array BioPharma Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - AVEO Pharmaceuticals, Inc. - Basilea Pharmaceutica AG - Bavarian Nordic A/S - Baxalta Incorporated - Bayer AG - BeiGene(Beijing) Co.,Ltd - BioAtla, LLC - Biocon Limited - Bionomics Limited - Bionovis SA - Biotecnol, Inc. For more information visit http://www.researchandmarkets.com/research/44...tal_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ADXS: 8.08 (-0.09), ARQL: 1.75 (-0.10), AMGN: 154.27 (-0.01), ATNM: 1.79 (-0.05), AZN: 30.15 (-0.27), AVEO: 0.93 (-0.01), ABBV: 61.92 (-0.79), BXLT: 46.02 (-0.18), ARRY: 3.62 (-0.01)
Metastatic Colorectal Cancer Pipeline Review, H2 2015
M2 - Mon Feb 08, 11:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/pdf2gt/metastatic) has announced the addition of the "Metastatic Colorectal Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Colorectal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Colorectal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Metastatic Colorectal Cancer Overview - Therapeutics Development - Pipeline Products for Metastatic Colorectal Cancer - Overview - Pipeline Products for Metastatic Colorectal Cancer - Comparative Analysis - Metastatic Colorectal Cancer - Therapeutics under Development by Companies - Metastatic Colorectal Cancer - Therapeutics under Investigation by Universities/Institutes - Metastatic Colorectal Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Metastatic Colorectal Cancer - Products under Development by Companies - Metastatic Colorectal Cancer - Products under Investigation by Universities/Institutes - Metastatic Colorectal Cancer - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - AB Science SA - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Advenchen Laboratories, LLC - Alchemia Limited - Amgen Inc. - Apexigen, Inc. - ArQule, Inc. - Array BioPharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Bavarian Nordic A/S - Baxalta Incorporated - Bayer AG - Biocon Limited - Bionovis SA - Biothera, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Celltrion, Inc. - Celon Pharma Sp. z o.o. - Cornerstone Pharmaceuticals, Inc. - DanDrit Biotech A/S - Dr. Reddy's Laboratories Limited - EirGenix Inc. - Eisai Co., Ltd. - Eli Lilly and Company - EnGeneIC Ltd - Epirus Biopharmaceuticals, Inc. - Etubics Corporation - Exelixis, Inc. For more information visit http://www.researchandmarkets.com/research/pdf2gt/metastatic
ARQL: 1.75 (-0.10), AMGN: 154.27 (-0.01), LLY: 79.64 (+0.69), BMY: 73.78 (unch), ATNM: 1.79 (-0.05), AZN: 30.15 (-0.27), AVEO: 0.93 (-0.01), ABBV: 61.92 (-0.79), BXLT: 46.02 (-0.18), EXEL: 8.05 (-0.12), CELGZ: 1.35 (-0.05), ARRY: 3.62 (-0.01)
Global Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Pipeline Review, H2 2015
M2 - Fri Feb 05, 10:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/rv4d7j/hormone) has announced the addition of the "Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Overview - Therapeutics Development - Pipeline Products for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Overview - Pipeline Products for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Development by Companies - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Investigation by Universities/Institutes - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Development by Companies - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Investigation by Universities/Institutes - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Companies Involved in Therapeutics Development Companies Featured - Partial List - A. Menarini Industrie Farmaceutiche Riunite Srl - AB Science SA - AbbVie Inc. - Adamis Pharmaceuticals Corporation - Advaxis, Inc. - Aeterna Zentaris Inc. - Alethia Biotherapeutics Inc. - Ambrx, Inc. - Amgen Inc. - AnGes MG, Inc. - Angion Biomedica Corp. - Aphios Corporation - Armour Therapeutics Inc. - Arno Therapeutics, Inc. - Arrowhead Research Corporation - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - Bavarian Nordic A/S - Bayer AG - Beta Pharma, Inc. - BIND Therapeutics, Inc. - Bio-Cancer Treatment International Limited - Biscayne Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CellCentric Ltd - Celldex Therapeutics, Inc. - Corcept Therapeutics Incorporated - CureVac GmbH - CytoVac A/S - DexTech Medical AB - Eisai Co., Ltd. - Eli Lilly and Company For more information visit http://www.researchandmarkets.com/research/rv4d7j/hormone
ADXS: 8.08 (-0.09), ARWR: 5.37 (-0.13), AMBX: (), CLDX: 4.52 (-0.07), ADMP: 3.19 (+0.24), AMGN: 154.27 (-0.01), LLY: 79.64 (+0.69), BIND: 0.73 (+0.33), BMY: 73.78 (unch), AZN: 30.15 (-0.27), ABBV: 61.92 (-0.79), CORT: 5.58 (+0.03)
Respiratory Syncytial Virus (RSV) Infections Pipeline Review, H2 2015
M2 - Tue Feb 02, 6:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/5krjz7/respiratory) has announced the addition of the "Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Respiratory Syncytial Virus (RSV) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Respiratory Syncytial Virus (RSV) Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Respiratory Syncytial Virus (RSV) Infections Overview - Therapeutics Development - Pipeline Products for Respiratory Syncytial Virus (RSV) Infections - Overview - Pipeline Products for Respiratory Syncytial Virus (RSV) Infections - Comparative Analysis - Respiratory Syncytial Virus (RSV) Infections - Therapeutics under Development by Companies - Respiratory Syncytial Virus (RSV) Infections - Therapeutics under Investigation by Universities/Institutes - Respiratory Syncytial Virus (RSV) Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Respiratory Syncytial Virus (RSV) Infections - Products under Development by Companies - Respiratory Syncytial Virus (RSV) Infections - Products under Investigation by Universities/Institutes - Respiratory Syncytial Virus (RSV) Infections - Companies Involved in Therapeutics Development - 3-V Biosciences, Inc. - Ablynx NV - ADMA Biologics, Inc. - Agilvax, Inc. - AmVac AG - Aridis Pharmaceuticals LLC - Bavarian Nordic A/S - Biota Pharmaceuticals, Inc. - Emergent BioSolutions Inc. - Evec, Inc. - F. Hoffmann-La Roche Ltd. - Folia Biotech Inc. - GenVec, Inc. - Gilead Sciences, Inc. - GlaxoSmithKline Plc - Globavir Biosciences, Inc. - Humabs BioMed SA - iBio, Inc. - ILiAD Biotechnologies, LLC - MedImmune, LLC - Medivir AB - Merck & Co., Inc. - MSM Protein Technologies, Inc. - Mucosis B.V. - NanoBio Corporation - Navigen Pharmaceuticals, Inc. - Romark Laboratories, L.C. - Sirnaomics, Inc. - Spider Biotech - Spring Bank Pharmaceuticals, Inc. - Takeda Pharmaceutical Company Limited - TechnoVax, Inc. - The International Biotechnology Center (IBC) Generium - Vaxart, Inc. - VBI Vaccines Inc. For more information visit http://www.researchandmarkets.com/research/5k...espiratory
ADMA: 6.26 (-0.09), EBS: 28.78 (+0.07), BOTA: 1.55 (-0.04), VBIV: 3.73 (-0.09), GSK: 43.50 (+0.33), GILD: 83.89 (-0.97), MRK: 58.00 (+0.06), IBIO: 0.67 (-0.07)
Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H2 2015 Featuring Bavarian Nordic, Emergent BioSolutions, Soligenix & Syntiron
M2 - Thu Jan 28, 4:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/fkk4sx/burkholderia) has announced the addition of the "Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Burkholderia pseudomallei Infections (Melioidosis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Burkholderia pseudomallei Infections (Melioidosis) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Burkholderia pseudomallei Infections (Melioidosis) Overview - Therapeutics Development - Pipeline Products for Burkholderia pseudomallei Infections (Melioidosis) - Overview - Pipeline Products for Burkholderia pseudomallei Infections (Melioidosis) - Comparative Analysis - Burkholderia pseudomallei Infections (Melioidosis) - Therapeutics under Development by Companies - Burkholderia pseudomallei Infections (Melioidosis) - Therapeutics under Investigation by Universities/Institutes - Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Burkholderia pseudomallei Infections (Melioidosis) - Products under Development by Companies - Burkholderia pseudomallei Infections (Melioidosis) - Products under Investigation by Universities/Institutes - Burkholderia pseudomallei Infections (Melioidosis) - Companies Involved in Therapeutics Development - Bavarian Nordic A/S - Emergent BioSolutions Inc. - Soligenix, Inc. - Syntiron LLC For more information visit http://www.researchandmarkets.com/research/fk...rkholderia
EBS: 28.78 (+0.07)
Bavarian Nordic Announces 3:1 Effective Split of American Depositary Shares
Thomson Reuters ONE - Tue Jan 05, 8:34AM CST
COPENHAGEN, Denmark, January 5, 2016 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that it will change the ratio of its American Depositary Shares ("ADSs"
, which are currently traded over-the-counter in the United States, from one (1) ADS per one (1) share of Bavarian Nordic, nominal value DKK 10 per share (each, a "Share" , to three (3) ADSs per one (1) Share. This ratio change is equivalent in effect to a 3:1 split of the ADSs. Each ADS currently represents an underlying interest in one (1) Share; following the ADS ratio change, each ADS will represent an underlying interest in one-third (1/3) of a Share, and three (3) ADSs will together represent an interest in one (1) Share. The record date for the ADS ratio change is January 15, 2016 (at close of business in New York) and the effective date for the ADS ratio change is January 19, 2016 (at open of business in New York). Bavarian Nordic Files Registration Statement for Proposed Initial Public Offering of ADSs in the United States
Thomson Reuters ONE - Mon Jan 04, 8:02AM CST
COPENHAGEN, Denmark, January 4, 2016 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today the filing of a Form F-1 Registration Statement with the U.S. Securities and Exchange Commission (the "SEC"
for a proposed initial public offering of American Depositary Shares ("ADSs" . The application is being made to list the ADSs on The NASDAQ Global Select Market in the United States under the symbol "BAVN." ADSs are U.S. dollar-denominated negotiable instruments issued by a depositary bank that facilitate U.S. trading and investment in shares of non-U.S. companies. The Form F-1 Registration Statement filed with the SEC will not contain any material information, not already published by Bavarian Nordic. Global Bavarian Nordic A/S Product Pipeline Review 2015
M2 - Thu Dec 24, 3:09AM CST
AcuteMarketReports.com has announced the addition of "Global Bavarian Nordic A/S Product Pipeline Review 2015 "Market Research Report to their Database.
Bavarian Nordic Enters Licensing and Collaboration Agreement with Janssen for MVA-BN(R) in the Development of a Therapeutic HPV Vaccine
Thomson Reuters ONE - Fri Dec 18, 12:31AM CST
- Total potential agreement value USD 171 million including upfront and milestone payments
